Literature DB >> 3006568

Long-term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. A longitudinal study.

M Melbye, R J Biggar, P Ebbesen, C Neuland, J J Goedert, V Faber, I Lorenzen, P Skinhøj, R C Gallo, W A Blattner.   

Abstract

The long-term effects of seropositivity for human T-lymphotropic virus type III (HTLV-III) on T-lymphocyte subsets and health status were evaluated in longitudinal studies of 250 initially healthy homosexual men. The relative risk of having an inverted T-lymphocyte helper-to-suppressor ratio rose from 14.3-fold among short-term seropositive subjects (less than 19 months) to 46.9-fold among long-term seropositive subjects (greater than 29 months) in comparison with the risk among seronegative subjects. Overall, 91.7% of long-term seropositive men had inverted ratios, compared with 12.9% of seronegative men. None of the seropositive men who developed an inverted ratio later reestablished a normal ratio. Both decreased T-helper cell number and percentage (p = 0.003) and increased T-suppressor cell number and percentage (p = 0.03) were significantly correlated with duration of seropositivity. Among seropositive persons, lymphadenopathy was a highly significant short-term as well as long-term consequence, whereas diarrhea, oral thrush, and herpes zoster were correlated with long-term seropositivity. Overall, 50% of long-term seropositive men compared with 16% of seronegative men developed at least one of five clinical symptoms (p less than 0.003). We conclude that a high proportion of persons infected with HTLV-III will develop measurable immunologic and clinical abnormalities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3006568     DOI: 10.7326/0003-4819-104-4-496

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  36 in total

1.  HIV INFECTION IN HERPES ZOSTER.

Authors:  Plk DE Sylva; K M Shah; H Mani; A K Hukkoo; S Bhattacharya; Yogesh Chander
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 2.  Is TNF involved in the progression of AIDS?

Authors:  N Kobayashi; Y Hamamoto; N Yamamoto
Journal:  Virus Genes       Date:  1990-07       Impact factor: 2.332

Review 3.  Why clinical trials of AIDS vaccines are premature.

Authors:  W K Mariner
Journal:  Am J Public Health       Date:  1989-01       Impact factor: 9.308

4.  Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.

Authors:  J M Lange; D A Paul; H G Huisman; F de Wolf; H van den Berg; R A Coutinho; S A Danner; J van der Noordaa; J Goudsmit
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

5.  Herpes zoster and the stage and prognosis of HIV-1 infection.

Authors:  A McNulty; Y Li; U Radtke; J Kaldor; R Rohrsheim; D A Cooper; B Donovan
Journal:  Genitourin Med       Date:  1997-12

6.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 7.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

8.  The clinical features of HIV infection in Africa.

Authors:  R J Biggar
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-06

9.  Biological significance of the antibody response to HIV antigens expressed on the cell surface.

Authors:  J Goudsmit; K Ljunggren; L Smit; M Jondal; E M Fenyö; M Jonda
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  Risk factors for HIV seropositivity among people consulting for HIV antibody testing: a pilot surveillance study in Quebec.

Authors:  M Alary; J Castel
Journal:  CMAJ       Date:  1990-07-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.